# EUS Guided Neurolysis Celiac Block w/wo Bupivacaine in Patient Being Treated Palliatively for Pancreatic Cancer

> **NCT02682082** · NA · TERMINATED · sponsor: **Centre hospitalier de l'Université de Montréal (CHUM)** · enrollment: 22 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **PROCEDURE:** Endoscopic ultrasound-guided celiax plexus neurolysis
- **DRUG:** Bupivacaine

## Key facts

- **NCT ID:** NCT02682082
- **Lead sponsor:** Centre hospitalier de l'Université de Montréal (CHUM)
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-05-27
- **Primary completion:** 2019-06-14
- **Final completion:** 2019-06-14
- **Target enrollment:** 22 (ACTUAL)
- **Why stopped:** Closed by CHUM REB for incomplete documentation of research activities.
- **Last updated:** 2020-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02682082

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02682082, "EUS Guided Neurolysis Celiac Block w/wo Bupivacaine in Patient Being Treated Palliatively for Pancreatic Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02682082. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*